|
PL2081929T3
(pl)
|
2006-11-08 |
2013-06-28 |
Neurocrine Biosciences Inc |
Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania
|
|
WO2010044981A2
(en)
|
2008-09-18 |
2010-04-22 |
Auspex Pharmaceutical ,Inc. |
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
CA2801061A1
(en)
*
|
2010-06-01 |
2011-12-08 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
WO2012000308A1
(zh)
*
|
2010-06-29 |
2012-01-05 |
中国药科大学 |
丁苯那嗪的拆分方法
|
|
US8351329B2
(en)
*
|
2010-09-14 |
2013-01-08 |
Cisco Technology, Inc. |
Universal load-balancing tunnel encapsulation
|
|
CN102285984B
(zh)
*
|
2010-11-25 |
2012-10-10 |
江苏威凯尔医药科技有限公司 |
(2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
|
|
WO2012081031A1
(en)
*
|
2010-12-15 |
2012-06-21 |
Enaltec Labs Pvt. Ltd. |
Process for preparing tetrabenazine
|
|
US9550780B2
(en)
|
2012-09-18 |
2017-01-24 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
CN104684555A
(zh)
|
2012-09-18 |
2015-06-03 |
奥斯拜客斯制药有限公司 |
囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
|
|
EA202091397A1
(ru)
*
|
2013-01-31 |
2020-09-04 |
Ауспекс Фармацетикалс, Инк. |
Бензохинолоновые ингибиторы vmat2
|
|
HK1221645A1
(zh)
*
|
2013-09-27 |
2017-06-09 |
Auspex Pharmaceuticals, Inc. |
Vmat2的苯并喹啉抑制剂
|
|
EA201791466A1
(ru)
*
|
2013-12-03 |
2017-11-30 |
Оспекс Фармасьютикалз, Инк. |
Способы получения соединений бензохинолина
|
|
EA201691512A1
(ru)
|
2014-01-27 |
2017-01-30 |
Оспекс Фармасьютикалз, Инк. |
Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2
|
|
US10166183B2
(en)
|
2014-02-07 |
2019-01-01 |
Auspex Pharmaceuticals, Inc. |
Pharmaceutical formulations
|
|
NZ760790A
(en)
*
|
2014-02-07 |
2022-11-25 |
Neurocrine Biosciences Inc |
Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
|
|
SI3105218T1
(sl)
|
2014-02-13 |
2019-11-29 |
Incyte Corp |
Ciklopropilamini kot inhibitorji LSD1
|
|
WO2015171802A1
(en)
*
|
2014-05-06 |
2015-11-12 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
|
|
CA2974540C
(en)
*
|
2015-02-06 |
2023-09-26 |
Neurocrine Biosciences, Inc. |
[9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
|
|
HRP20221106T1
(hr)
|
2015-03-06 |
2022-11-25 |
Auspex Pharmaceuticals, Inc. |
Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
|
|
EP3277689B1
(en)
|
2015-04-03 |
2019-09-04 |
Incyte Corporation |
Heterocyclic compounds as lsd1 inhibitors
|
|
EA036837B1
(ru)
*
|
2015-06-23 |
2020-12-25 |
Нейрокрин Байосайенсиз, Инк. |
Ингибиторы vmat2 для лечения неврологических заболеваний или расстройств
|
|
LT3334709T
(lt)
|
2015-08-12 |
2025-03-10 |
Incyte Holdings Corporation |
Lsd1 inhibitoriaus druskos
|
|
MX383906B
(es)
|
2015-10-09 |
2025-03-14 |
Teva Pharmaceuticals Int Gmbh |
Combinación de levodopa deuterado con carbidopa y opicapona para el tratamiento del mal de parkinson
|
|
MY193767A
(en)
*
|
2015-10-30 |
2022-10-27 |
Neurocrine Biosciences Inc |
Valbenazine salts and polymorphs thereof
|
|
CN108925135B
(zh)
*
|
2015-12-23 |
2025-09-19 |
纽罗克里生物科学有限公司 |
制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
|
|
US10479787B2
(en)
|
2016-04-22 |
2019-11-19 |
Lupin Limited |
Process for preparation of tetrabenazine and deutetrabenazine
|
|
US10442800B2
(en)
*
|
2016-06-29 |
2019-10-15 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Crystal forms of NBI-98854, preparation method and use thereof
|
|
EP3523300A1
(en)
|
2016-10-06 |
2019-08-14 |
Assia Chemical Industries Ltd. |
Solid state forms of valbenazine
|
|
TW202345829A
(zh)
|
2016-12-02 |
2023-12-01 |
美商紐羅克里生物科學有限公司 |
戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
|
|
EP3568394A1
(en)
|
2017-01-10 |
2019-11-20 |
Sandoz AG |
Crystalline valbenazine free base
|
|
WO2018140092A1
(en)
|
2017-01-27 |
2018-08-02 |
Obrien Christopher F |
Methods for the administration of certain vmat2 inhibitors
|
|
CA3054238A1
(en)
|
2017-02-27 |
2018-08-30 |
Sandoz Ag |
Crystalline forms of valbenazine salts
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
UA127052C2
(uk)
|
2017-03-15 |
2023-03-29 |
Оспекс Фармасьютікалс, Інк. |
Аналоги деутетрабеназину, їхнє отримання та застосування
|
|
GB201705302D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
JP7250692B2
(ja)
*
|
2017-04-01 |
2023-04-03 |
アデプティオ ファーマシューティカルズ リミテッド |
運動障害の治療における使用のためのジヒドロテトラベナジン
|
|
GB201705306D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705304D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705303D0
(en)
*
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705305D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
JOP20190239A1
(ar)
|
2017-04-19 |
2019-10-09 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات منها
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
ES3024958T3
(en)
|
2017-09-21 |
2025-06-05 |
Neurocrine Biosciences Inc |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
|
JP2021502959A
(ja)
|
2017-10-10 |
2021-02-04 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
特定のｖｍａｔ２インヒビターを投与するための方法
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
CA3081709A1
(en)
*
|
2017-11-08 |
2019-05-16 |
Yuhua Li |
Esters of dihydrotetrabenazine
|
|
EP3713938A1
(en)
|
2017-11-22 |
2020-09-30 |
Assia Chemical Industries Ltd |
Solid state form of valbenazine
|
|
CA3086611C
(en)
|
2017-12-26 |
2023-07-25 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
|
|
CN110092785A
(zh)
*
|
2018-01-31 |
2019-08-06 |
广东东阳光药业有限公司 |
一种丁苯那嗪的动态拆分方法
|
|
GB201808464D0
(en)
|
2018-05-23 |
2018-07-11 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compounds for use in treating huntington's disease
|
|
MX2020013004A
(es)
*
|
2018-06-14 |
2021-02-17 |
Neurocrine Biosciences Inc |
Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
|
|
SG11202100303QA
(en)
|
2018-08-15 |
2021-02-25 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2020047198A1
(en)
|
2018-08-31 |
2020-03-05 |
Incyte Corporation |
Salts of an lsd1 inhibitor and processes for preparing the same
|
|
EP3860599B1
(en)
|
2018-10-04 |
2024-05-15 |
Adeptio Pharmaceuticals Limited |
(+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
|
|
CA3065236A1
(en)
|
2018-12-27 |
2020-06-27 |
Apotex Inc. |
Novel crystalline form of valbenazine dibesylate
|
|
WO2020213014A1
(en)
|
2019-04-19 |
2020-10-22 |
Mylan Laboratories Limited |
An improved process for the preparation of valbenazine and its salts
|
|
US10689380B1
(en)
|
2019-07-30 |
2020-06-23 |
Farmhispania S.A. |
Crystalline forms of valbenazine ditosylate
|
|
US12565495B2
(en)
*
|
2019-08-12 |
2026-03-03 |
Luye Innomind Pharma Shijiazhuang Co., Ltd. |
VMAT2 inhibitor and preparation method therefor and application thereof
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
JP2022547990A
(ja)
|
2019-09-13 |
2022-11-16 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
バルベナジンの合成のための方法
|
|
CN110698397A
(zh)
*
|
2019-10-28 |
2020-01-17 |
南京红杉生物科技有限公司 |
丁苯那嗪中间体及其合成方法、应用和合成用中间产物
|
|
PT4168409T
(pt)
|
2021-03-22 |
2025-06-12 |
Neurocrine Biosciences Inc |
Inibidores de vmat2 e métodos de utilização
|
|
US20240239791A1
(en)
|
2021-04-26 |
2024-07-18 |
Neurocrine Biosciences, Inc. |
Processes for the synthesis of valbenazine
|
|
BR112023026691A2
(pt)
|
2021-06-30 |
2024-03-05 |
Neurocrine Biosciences Inc |
Valbenazina para uso no tratamento complementar de esquizofrenia
|
|
MX2023014977A
(es)
|
2021-06-30 |
2024-02-09 |
Neurocrine Biosciences Inc |
Valbenazina para usarse en el tratamiento de discinesia debido a paralisis cerebral.
|
|
WO2023172849A1
(en)
|
2022-03-07 |
2023-09-14 |
Neurocrine Biosciences, Inc. |
Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
|
|
TW202421131A
(zh)
|
2022-09-21 |
2024-06-01 |
美商紐羅克里生物科學有限公司 |
Vmat2抑制劑及其使用方法
|
|
WO2025038959A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025038938A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Valbenazine for use in the treatment of huntington's chorea
|
|
WO2025096823A1
(en)
|
2023-11-01 |
2025-05-08 |
Neurocrine Biosciences, Inc. |
Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
|
|
WO2025188830A1
(en)
|
2024-03-06 |
2025-09-12 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025199234A1
(en)
|
2024-03-20 |
2025-09-25 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors and methods of use
|
|
WO2026050236A1
(en)
|
2024-08-27 |
2026-03-05 |
Neurocrine Biosciences, Inc. |
Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder
|